Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer
TMB, somatic BRAF status and systemic inflammation should be prospectively investigated as practical biomarkers for predicting potential responsiveness to immune checkpoint inhibitors in metastatic microsatellite-stable/mismatch repair-proficient colorectal cancer.
Authors
- Benjamin P. Geisler (ORCID: https://orcid.org/0000-0003-1704-6067)
- Sebastian Meltzer (ORCID: https://orcid.org/0000-0001-6640-3927)
- Eva Hofsli (ORCID: https://orcid.org/0000-0001-9856-4880)
- Halfdan Sørbye (ORCID: https://orcid.org/0000-0002-7132-6214)
- Christian Kersten (ORCID: https://orcid.org/0000-0002-5691-2944)
- Hanne Hamre
- Jens Petter Berg (ORCID: https://orcid.org/0000-0003-0157-5888)
- Paula A. Bousquet (ORCID: https://orcid.org/0000-0002-6653-2195)
- Torben Lüders
- Diana L. Bordin
- Anne Hansen Ree
- Tina Visnovska
- Hilde L. Nilsen
- Marianne G. Guren
- Shixiong Wang
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Akershus University Hospital (NO)
- Haukeland University Hospital (NO)
- St Olav's University Hospital (NO)
- Sørlandet Sykehus (NO)
- University of Bergen (NO)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1038/s41416-026-03357-6
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Helse Sør-Øst RHF